

## Advances in Immunotherapy and Vaccine for Prostate Cancer

Wei Zhou<sup>1</sup>, Yikai Zhang<sup>2</sup>

Cite this article: Zhou W, Zhang Y: Advances in Immunotherapy and Vaccine for Prostate Cancer. *Ann Urol Oncol* 2023, 6: 9. <https://doi.org/10.32948/auo.2023.05.27>

### Abstract

Prostate cancer is one of the most common malignant tumors of the urinary system. The incidence of prostate cancer is high in the elderly male patients, which seriously threatens the life and health. In recent years, immunotherapy to activate anti-cancer host immune cells to kill tumors has become a new area of research for the treatment of prostate cancer. As an important component of immunotherapy, cancer vaccines have a unique position in the precise treatment of malignant tumors. There are many types of prostate cancer vaccines, including monocyte vaccines, dendritic cell vaccines, viral vaccines, peptide vaccines, and DNA/mRNA vaccines, etc. As the most important cancer vaccine based on monocytes, it is the only prostate cancer therapeutic vaccine approved by the US Food and Drug Administration at present, which plays an extremely important role in the immunotherapy of prostate cancer. However, due to its own limitations, Sipuleucel-T has not been widely adopted. Currently, the complexity of immunotherapy and the specificity of prostate cancer mean that other prostate cancer vaccines have not shown expected clinical benefits in large randomized phase II and III trials, and further in-depth studies are still needed.

**Key words** prostate cancer, cancer vaccine, sipuleucel-T, immunotherapy

1. No.986 Air Force Hospital, Xi'an City, Shaanxi Province, China.

2. Shaanxi Institute of Medical Device Quality, Xi'an City, Shaanxi Province, China.

Correspondence: Yikai Zhang (Shaanxi Institute of Medical Device Quality, No. 6 Jianshe West Road, Xi'an, Shaanxi Province, 710032, China; Email: 462473874@qq.com).

## Introduction

Prostate cancer rates have been on the rise in recent years. In 2020, prostate cancer remains the most common malignancy among men worldwide. In China, prostate cancer has become an important factor in threatening the life safety of men [1, 2]. Global Cancer statistics and Chinese Cancer statistics [3-5] show that in recent years, prostate cancer rates continue to rise. Currently, most men with advanced prostate cancer develop castration-resistant prostate cancer (CRPC) [6]. How to further improve the efficacy of CRPC while reducing adverse reactions, has become a focus in this field. In the past decades, immunotherapy has been used to treat prostate cancer through anti-tumor effects driven by immune response. It has brought new immunotherapeutic opportunities. Sipuleucel-T is strongly supported by the U.S. Food and Drug Administration for the treatment of CRPC and has shown promising results. Pembrolizumab has become an important therapeutic tool for prostate cancer immunotherapy [7, 8]. Cancer vaccines use tumor cell-associated antigens to induce a specific anti-tumor immune response that is durable and robust. As an important part of immunotherapy, cancer vaccines have unique and significant advantages against prostate cancer, including monocyte vaccines and dendritic cells, vaccines, viral vaccines, peptide vaccines and DNA/mRNA vaccines [9]. Among them, Sipuleucel-T plays a great role in promoting prostate cancer immunotherapy. Therefore, this article reviews the latest progress on prostate cancer vaccine, especially Sipuleucel-T vaccine based on mononuclear cells.

**Figure 1** shows that general view of vaccine for prostate cancer.

## Monocyte-based vaccines

### *Sipuleucel-T*


Sipuleucel-T (Provenge®, Dendreon, USA) is an active immune cell-based immunotherapy that induces an immune response against prostate acid phosphatase (PAP). Prostate acid phosphatase (PAP) is expressed in approximately 95% of prostate cancers and is mainly limited to prostate tissue, which is a target for prostate cancer tumor vaccine development. It is a type of autologous immunotherapeutic vaccine, composed of peripheral mononuclear cells. Sipuleucel-T consists of autologous peripheral blood mononuclear cells including antigen presenting cells (APCs). Peripheral blood mononuclear cells from patients were obtained by a standard procedure of leukocyte separation approximately 3 days prior to infusion. To increase the immune response to PAP, it is activated by adding PAP and the recombinant fusion protein of immune activator GM-CSF (PAP-GM-CSF) at a specific stage of cell culture. The active components of Sipuleucel-T are autologous APCs and PAP-GM-CSF, in addition to T cells, B cells, natural killer cells, and other cells that specifically bind to PAP expressed in prostate cancer tissue to kill tumor cells. The technology causes patients' own immune system to respond to prostate cancer. In 2010, the US Food and Drug Administration (FDA) approved it into the clinic, and it is the only cell active immune product licensed to treat asymptomatic or mild CRPC [10, 11]. The patient's peripheral blood mononuclear cells (PBMC) rich in antigen-presenting cells (APC) were collected by leukapheresis. After incubating with PA2024 in vitro, the activated cells were injected a new APC, which elicits an antitumor immune response. Among them, PA2024 is the carboxyterminal terminus of PAP and the granulocyte-macrophage colony-stimulating factor (GM-CSF). The amino terminal of GM-CSF was linked to the recombinant protein (PAP-GM-CSF). The whole procedure, including leukapheresis, cell activation and reinfusion, repeated every 2 weeks for a total of 3 times (weeks 0, 2 and 4) [12].

IMPACT(NCT00065442) phase III randomized, double-blind,

placebo clinical trial [13], where 512 patients were randomly assigned to receive Sipuleucel-T or placebo (2:1). After a median follow-up of 34.1 months, the results showed that: Compared with placebo group (121 patients, 70.8%), Sipuleucel-T group (210 patients, 61.6%) had a 22% relative reduction in the risk of death, and the adjusted hazard ratio for death was 0.78 (95%CI: 0.61-0.98,  $P=0.03$ ). The median overall survival (OS) was improved by 4.1 months (25.8 months vs 21.7 months). The estimated 36-month survival rate was 31.7% (vs. 23.0% with placebo); In another exploratory study, baseline PSA was found to be a predictor of Sipuleucel-T efficacy [14]. In this study, all patients were divided into four groups on average, with 128 patients in each group. Baseline PSA values (ng/ml) were  $\leq 22.1$ ,  $> 22.1-50.1$ ,  $> 50.1-134.1$ , and  $> 134.1$ , respectively. The group with the best Sipuleucel-T efficacy was the group with the lowest PSA interval. The median OS in the treatment and control groups was 41.3 and 28.3 months, respectively, while the median OS in the treatment and control groups for the highest PSA interval was 18.4 and 15.6 months.. The study concluded that while Sipuleucel-T is effective in all patients, it is most effective in patients predicted to have a lower risk of progression, so the earlier Sipuleucel-T is used, the better is the treatment response. Sipuleucel-T can only be used by the patient. Before infusion, the patient's identity must be confirmed to match that marked on the infusion bag. When given 3 times, about 2 weeks apart from each treatment, OS of patients with advanced prostate cancer can be significantly improved and the average survival time can be extended by more than 4 months. The most common adverse events (incidence  $\geq 15\%$ ) included chills, fatigue, fever, back pain, nausea, joint pain, and headache. Sipuleucel-T was well tolerated, and the most common adverse events were fever and influenza-like symptoms. However, it is worth noting that there was no significant difference in progression-free survival (PFS) or prostate specific antigen (PSA) decline between the two groups. Less than 3% of Sipuleucel-T patients had a PSA decline of 50% or more. Based on the IMPACT [13], D9901 (NCT00005947) [15], D9902A(NCT01133704) [16], double-blind, controlled, multicenter phase III randomized trials, in April 2010, the FDA officially approved Sipuleucel-T as the first prostate cancer vaccine for the treatment of asymptomatic or mildly symptomatic mCRPC [8]. The clinical use of this drug has greatly promoted the development of cancer vaccines, but unfortunately, prostate cancer vaccines other than Sipuleucel-T have not shown promising clinical benefit in large, randomized phase II and III trials.

### *Immunologic Mechanism of Action of Sipuleucel-T*

The immune response induced by Sipuleucel-T is multifaceted, and APC-mediated immune response is the basis of its action, that is, it induces the body to produce PAP specific T cells and B cells, thereby activating the body's immune response to prostate cancer and generating an anticancer effect. The specific mechanisms of sipuleucel-T are as follows: 1) APC activation and immune enhancement. Increased cumulative APC activation, a measure of product potency and immune activation, was statistically significantly associated with improved OS. Sipuleucel-T infusions at weeks 2 and 4 resulted in increased APC activation. This indicates that the first infusion (week 0) primes the immune system and subsequent treatments enhance the immune response. Meanwhile, APC activation is more effective in patients with early prostate cancer [17]. 2) Generate specific immune responses against PAP and PA2024. 3) Antigen diffusion. After an initial immune response to a specific target antigen, Sipuleucel-T expands its response to other antigens expressed by the tumor, which is known as antigen diffusion. In this process, tumor cells lysed by antigen-specific T cells release additional tumor-associated antigens (TAA), which are eventually expressed by the tumor-



associated antigens. APC processing and presentation to induce B cells and T cells to produce immune responses against secondary antigens (such as E-RAS, KLK2, K-RAS, LGALS3 and LGALS8, etc.), which are closely related to the improved survival benefits of Sipuleucel-T [18, 19]. 4) T cell reactive transfer and cytotoxic T lymphocyte (CTL) activity. Fong et al.[20] pointed out that neoantigen Sipuleucel-T could induce systemic antigen-specific T cell response and activation effect before radical prostatectomy.

Efficacy evaluation. The IMPACT study [13] showed that Sipuleucel-T could prolong the median OS of mCRPC patients. Schellhammer et al. [14] pointed out that PSA was a strong predictor of Sipuleucel-T treatment response ( $P < 0.0001$ ), and with the decrease of baseline PSA, Sipuleucel-T treatment response would be greater. The hazard ratio for OS was 0.51 (95% CI: 0.31-0.85) in patients with baseline PSA  $\leq 22.1$  ng/mL and 0.84 (95% CI: 0.31-0.85) in patients with PSA  $> 134$  ng/mL. (0.55 to 1.29), indicating a benefit of Sipuleucel-T at an earlier stage of cancer. Early use of Sipuleucel-T has less tumor immunosuppression and more APC activation, which is more conducive to the long-term stimulation of immune response and long-term clinical benefit. Another notable clinical feature of Sipuleucel-T is the delayed effect, in which proximal end points such as PSA levels, objective disease progression, and the occurrence of disease-related pain

are not altered. In contrast, there was an improvement in the distal end points [24]. Small et al. [25] found that Sipuleucel-T treatment was not associated with time to disease-related pain (TDRP) (HR=0.819, 95% CI: 0.616-1.089,  $P=0.170$ ), which was associated with delayed time to first use of opioid analgesics (TFOA) (HR=0.755, 95%CI: 0.579-0.985,  $P=0.038$ ). These changes in late outcomes may be related to the time required to exert the immune antitumor effect after Sipuleucel-T treatment. Sipuleucel-T results were also variable in different ethnic groups.

The PROCEED study [26] showed that compared with whites, African Americans had a higher median OS after Sipuleucel-T treatment (HR= 0.81, 95%CI: 0.68-0.97,  $P=0.03$ ). This may be related to the differences in the immune system between different ethical backgrounds [27].

The value of drug combinations. Prostate cancer has a low mutation burden and a small number of tumor infiltrating CD8+ T cells, which makes prostate cancer a "cold tumor" of immune response, resulting in a far worse effect of immunotherapy than other solid tumors [28]. Therefore, combination therapy is commonly used in prostate cancer immunotherapy. Theoretically, combination of Sipuleucel-T with the activation and spread of the immune response, combined with the durable efficacy and safety profile, offers the promise of prolonged anticancer activity and is of great value. A randomized phase II open-label trial evaluated Sipuleucel-T versus androgen deprivation therapy (ADT) in the treatment of patients with biochemical recurrence. The results showed that the safety of different administration sequences was good. The PA2024-specific T cell response of Sipuleucel-T first was higher than that of ADT first ( $P= 0.001$ ), which could induce greater anti-tumor immune response [29]. The results of a mathematical model for Sipuleucel-T and ADT response in prostate cancer developed by Jain et al. [30] showed that 2 doses of vaccine administered before ADT was optimal, reducing cancer mortality by approximately 45% and maximizing median OS. Small et al. [31] randomized phase II trial evaluating Sipuleucel-T combined with abiraterone in the treatment of mCRPC showed that simultaneous administration did not attenuate or change the immune effect of Sipuleucel-T, and the combination was well tolerated. Radiotherapy (hereafter referred to as radiotherapy) and chemotherapy (hereafter referred to as chemotherapy) may synergize with immunotherapy to enhance and expand antitumor immune responses. However, in a randomized phase II trial of Sipuleucel-T combined with radiotherapy, irradiation of up to 30 Gy to a single metastatic site in asymptomatic or minimally symptomatic mCRPC patients did not enhance the immune response associated with Sipuleucel-T treatment [32]. With respect to combination chemotherapy, few studies have been conducted, and two clinical trials evaluating the sequencing of Sipuleucel-T plus docetaxel (NCT02793219 and NCT02793765) were withdrawn with reduction in demand. In addition, a randomized phase II trial of Sipuleucel-T combined with radium 223 in the treatment of bone metastatic mCRPC showed that the combination therapy could improve clinical efficacy, but the immune response was low [33]. Due to the lack of effector T cell infiltration in the tumor microenvironment (TME), the efficacy of immune checkpoint inhibitors (ICI) monotherapy in the treatment of prostate cancer is not good. More recently, Sinha et al. [34] combined Sipuleucel-T and ipilimumab, showing that combination therapy produced modest clinical responses without changing antigen-specific responses. The phase Ib study by Dorff et al. [35] on mCRPC patients who received different sequential regimens of atezolizumab, and Sipuleucel-T showed that the combination therapy was safe and may be more beneficial regardless of the order of administration. At the same time, other emerging therapies, such as the combination of cytokine IL-7, have also achieved encouraging results in phase II trials [36]. Currently,

compared with other immunotherapies, Sipuleucel-T is not widely used, in part because its clinical success rate is limited, and the cost associated with its treatment is not acceptable to most patients. However, the immunologic benefit of Sipuleucel-T in combination therapy still sets the stage for additional large trials.

Clinical limitations "A survey of factors associated with the use of Sipuleucel-T in mCRPC patients in the United States [37] showed that only 730 of 7272 patients treated received Sipuleucel-T, and ethnicity, region of residence, income, and professional recommendation were associated with its use." From a cost perspective, Sipuleucel-T requires three infusions over a period of 1 month. However, the cost-effectiveness analysis for the treatment of mCRPC patients found that the treatment strategy without sipuleucel-T could show the most favorable incremental cost-effectiveness ratios (ICER) [38]. At the same time, the delayed effect of Sipuleucel-T, resulting in the lack of PSA or objective response in clinical trials, affects the assessment of disease progression. Currently, Sipuleucel-T is not widely adopted outside the United States. This drug has been discontinued in Europe because of its complex management, low survival benefit, and high price [39]. Its owner, Dendreon, went bankrupt due to production capacity and financial problems, and was completely acquired by China's Sanpower Group.

### Dendritic cell vaccine

DCVAC/PCa vaccine is a PBMC-derived autologous dendritic cell vaccine that can be generated by pulsing PBMC obtained by apheresis with killed prostate cancer cells (LNCaP) followed by subcutaneous injection of mature dendritic cells [40]. Two phase I/II small sample clinical trials [41, 42] have shown that DCVAC/PCa has a good safety profile in the treatment of prostate cancer and can improve the prostate-specific antigen doubling time (PSA). PSADT was significantly prolonged ( $P<0.001$  8). At present, there are few basic and clinical studies on the vaccine. One trial evaluated DCVAC/ PCa combined with first-line chemotherapy (docetaxel plus prednisone) in patients with mCRPC. The results of a randomized, double-blind, phase III trial of the safety and efficacy of DCVAC/PCa in combination with a single-line chemotherapy agent [43] showed that DCVAC/ PCA [maintain consistency and define] in combination with a single-line chemotherapy agent did not prolong OS in mCRPC patients (23.9 months vs 24.3 months, HR: Hr: 1.04, 95% CI: 0.90-1.21,  $P=0.60$ ).

### Cancer cell vaccine

The GVAX/PCa vaccine is a genetically transfected cancer cell vaccine in which the tumor cells provide the antigen. The GVAX/PCa vaccine uses LNCaP, and PC-3 cell lines to secrete GM-CSF [44]. A phase I/II trial in patients with hormone-naïve prostate cancer and PSA recurrence [45] showed that 76% (16/21) of patients had a significant PSA reduction 20 weeks after the first treatment. Higano et al. [46] showed that the proportion of mCRPC patients who developed antibodies to GVAX increased with increasing doses. These promising results prompted 2 phase III trials. The VITAL-1 trial randomized asymptomatic patients with chemotherapy-naïve mCRPC to GVAX or more Cetaxel + prednisone group; The VITAL 2 trial randomly assigned symptomatic patients with chemotherapy-naïve mCRPC to GVAX plus docetaxel or docetaxel plus prednisone. It was disappointing that VITAL was stopped early after a preliminary analysis showed a survival advantage for the docetaxel-plus-prednisone group and a disproportionate number of deaths in the GVAX group. Subsequently, the VITAL-1 trial was terminated prematurely due to a possible failure to improve survival [47].

**Table 1. Overview of prostate cancer vaccines.**

Vaccine	Type	Mechanism of action	Clinical stage	Results	State	Reference
Sipuleucel-T	Monoct vaccine	Immunotherapy based on active immune cells can induce targeting prostatic acid phosphatase prostate acid phosphatase (PAP) anti-tumor immune response.	Stage III	Improve median survival Phase 4.1 months	On the market	[7-9], [11-39]
DCVAC/PCa	Dendritic Cellular vaccine	Peripheral blood mononuclear cells (mononuclear cells) obtained by apheresis cell, PBMC) is pulsed with killed prostate cancer cells (LNCaP) and re-skinned mature dendritic cells are injected below to obtain an antitumor immune response.	Stage III	Unprolonged patient Median survival	Finished	[40-43]
GVAX/PCa	Cancer cell vaccine	After gene transfection, LNCaP and PC-3 cell lines were used to secrete granulocyte-macrophage factor(granulocyte-macrophage colony-stimulating factor, GM-CSF) to produce an antitumor immune response.	Stage III	Unprolonged patient Median survival	Early termination	[44-47]
PROSTVAC (PSA-TRICOM)	Viral vector vaccine	A plasmid with PSA-TRICOM is inserted into a poxvirus. Patients first receive an initial vaccine for recombinant vaccinia (Prostvac-V), followed by multiple booster immunizations with recombinant avian pox (Prostvac-F).	Stage III	Unprolonged patient Median survival	Early termination	[48-51]
Adenovirus /PSA	Viral vector vaccine	Adenovirus /PSA can be used to induce an immune response against PSA and target the killing of tumor cells.	Stage I / II	The vaccine is immunogenic	Be in progress	[52-54]
PPV	Polypeptide vaccine	Will feed specific tumor antigen peptide antigen presenting cells (antigen presenting cell, APC) on the surface of the major histocompatibility complex, forming peptide - MHC - which is complex, so as to stimulate cytotoxic T lymphocyte (cytotoxic T lymphocyte, CTL) response, producing antitumor immunity.	Stage III	Unprolonged patient Median survival	Finished	[55, 56]
GX301	Polypeptide vaccine	A vaccine consisting of four telomerase peptides and two immune adjuvants (Montanide ISA-51 and imiquimod).	Stage II	The vaccine is immunogenic	Be in progress	[57, 58]
DNA/ mRNA vaccine	DNA/ mRNA vaccine	DNA vaccine is a closed circular DNA plasmid designed by the target antigen, which encodes the antigen under the action of the powerful promoter of mammals, and improves the immunogenicity through the targeted antigen presentation. mRNA vaccines deliver mRNA sequences that encode protein antigens into the body, causing the body to express the corresponding protein and inducing an immune response against the protein.	Stage I / II	The vaccine is immunogenic	Be in progress	[59-67]



## Viral vaccines

### PSA-TRICOM

Psa-tricom (Prostvac) is a viral vector-based vaccine produced by inserting a recombinant plasmid with a PSA transgene into a poxvirus together with a plasmid encoding three viral T-cell costimulatory molecules (TRICOM). Patients first receive primary immunization with recombinant vaccinia (Prostvac-V), followed by multiple booster immunization with recombinant avian pox (Prostvac-F) [48]. TRICOM, which is composed of B7.1, ICAM-1 and LFA-3, is mainly used to improve T cell affinity and increase tumor cell lysis [49]. The results of phase II trial showed that patients receiving Prostvac-V/F had a prolonged median OS of 8.5 months (25.1 months vs 16.6 months), with an estimated hazard ratio of 0.56 (95%CI: 0.37-0.85,  $P=0.0061$ ) and a 44% reduction in mortality [50]. This result strongly encourages subsequent phase III trials. The development of cancer vaccines has also set off a new climax. However, the subsequent phase III trial showed that there was no difference in OS between Prostvac group, proSTVAC-GM-CSF group and placebo group, and the trial was terminated prematurely [51].

### Adenovirus /PSA

Adenoviruses were originally used as vectors for gene therapy. In recent years, with the higher safety and high immunogenicity of genetically modified products and the development of next-generation vectors, their utility as vaccine vectors has been increasing [52]. Animal experiments have shown that adenovirus /PSA (Ad5-PSA) can induce immune response against PSA and target killing tumor cells [53]. A phase I clinical trial showed that the treatment of mCRPC patients with adenovirus /PSA was safe, and most patients could produce anti-PSA T cell responses. However, the current research on this vaccine is still in phase I/II trials with small samples, and there are few related phase III trials [54].

## Peptide vaccine

### Individualized peptide vaccines

Personalized peptide vaccines (PPV) are tumor vaccines that are produced by selecting individual peptides for vaccination based on individual genetic structure and functional differences. The mechanism of PPV is that the specific tumor antigen peptide is delivered to the major histocompatibility complex (MHC) on the surface of APC, which is degraded into short peptides in APC and forms peptide-MHC-TCR complex, which is recognized by T cells. The corresponding CTL response is stimulated, thereby carrying out anti-tumor immunity [55]. A randomized, double-blind, placebo-controlled phase III trial of PPV in patients with CRPC who progressed after docetaxel chemotherapy [56] showed that PPV did not prolong OS ( $P=0.77$ ). Subgroup analysis showed that patients with lower percentage of neutrophils or higher percentage of lymphocytes at baseline could benefit from PPV treatment.

### GX301

GX301 is a vaccine consisting of four telomerase peptides and two immune adjuvants (Montanide ISA-51 and imiquimod). It was found to be safe and immunogenic in phase I trials [57]. The results of a multicenter, randomized, parallel-group, open-label phase II trial showed that GX301 vaccine was safe and immunogenic in patients with mCRPC, and the immune response rate was related

to the number of immunizations, which provided a reference for treatment options in future studies [58].

## DNA/mRNA vaccine

DNA vaccines are closed circular DNA plasmids designed using target antigens, encoding antigens under the action of a strong mammalian promoter, and improving immunogenicity through targeted antigen presentation to kill tumor cells. Currently, DNA-based prostate cancer vaccines mainly include vaccines encoding PAP, PSMA, PSA, etc.[59]. A phase I/IIa trial of encoded PAP [60] showed that the vaccine had a good safety profile, with 14% (3/22) of patients producing PAP-specific IFN- $\gamma$ -secreting CD8+ T cells immediately after treatment. PAP specific CD4+ and/or CD8+ T cell proliferation was observed in 41% (9/22) patients, and the difference in PSADT was statistically significant ( $P<0.05$ ). Similarly, the safety and efficacy of DNA vaccine encoding PSMA were also confirmed in phase I/II trials, and its PSADT was significantly increased ( $P=0.0417$ ) [61]. A recent study [62] showed that PSMA or T-cell receptor  $\gamma$  alternate reading frame protein, peptides of TARP, incorporated into spherical nucleic acid (SNA) vaccines with optimized structures, can significantly affect adaptive immune responses to clinically used prostate cancer targets.

This may become a new research direction in the future. The mRNA vaccine is a synthetic protein antigen encoded by the mRNA sequence delivered to the body to cause the body to express the corresponding protein and induce the body to produce an immune response against the protein to achieve the purpose of disease prevention and treatment [63-65]. Among them, safe and efficient delivery system is the core key technology of mRNA vaccine development [66]. Currently, mRNA vaccines for prostate cancer are under development. To address the bottleneck of tumor antigen screening and vaccine candidates, Zheng et al. [67] showed that KLHL17, CPT1B, IQGAP3, LIME1, YJEFN3, KIAA1529, MSH5, and CELSR3 are important markers of prostate adenocarcinoma. Patients with PRAD immune subtype (PIS) 2 and 3 are more suitable for vaccination. The mechanisms of action and study results of these different types of vaccines are shown in Table 1.

## Concluding Remarks

In recent years, remarkable progress has been made in prostate cancer immunotherapy, and a variety of new therapies have emerged. As the only prostate cancer vaccine that has been used in clinical practice so far, Sipuleucel-T plays a crucial role in promoting the progress of prostate cancer immunotherapy. However, cancer vaccines are limited to their own characteristics and have not shown greater clinical benefits compared with other therapies. Therefore, there is a need to further improve the cancer vaccination strategy, improve the design of Sipuleucel-T, and find evaluation indicators. It is anticipated that with the continuous optimization of Sipuleucel-T, its advantages in the targeted therapy of prostate cancer will become more significant, and more reasonable combination therapy in the future will continue to improve the tumor killing effect of immunotherapy.

## Acknowledgements

We thank Dr. Sanjay Gupta (Case Western Reserve University & UH Cleveland Medical Center) for his proofreading for the review.

## Ethical policy

All procedures performed in this study were in accordance with

the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Approval from institutional ethical committee was taken.

### Availability of data and materials

All data generated or analysed during this study are included in this publication.

### Author contributions

ZW designed the study and was responsible for the writing of the original draft. ZY edited and approved the final manuscript.

### Competing interests

All authors declare no competing interests.

### Funding

None.

### References

- Carlsson SV, Vickers AJ: Screening for Prostate Cancer. *Med Clin North Am* 2020, 104(6): 1051-1062.
- Dörr M, Hölzel D, Schubert-Fritschle G, Engel J, Schlesinger-Raab A: Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. *Oncol Res Treat* 2015, 38(1-2): 8-14.
- Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer statistics, 2022. *CA Cancer J Clin* 2022, 72(1): 7-33.
- Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N et al: Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl)* 2022, 135(5): 584-590.
- Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, Zeng HM, Wei WW, He J: [Cancer statistics in China, 2016]. *Zhonghua Zhong Liu Za Zhi* 2023, 45(3): 212-220.
- Merseburger AS, Alcaraz A, von Klot CA: Androgen deprivation therapy as backbone therapy in the management of prostate cancer. *Onco Targets Ther* 2016, 9: 7263-7274.
- DeFrancesco L: Landmark approval for Dendreon's cancer vaccine. *Nat Biotechnol* 2010, 28(6): 531-532.
- Marcus L, Lemery SJ, Keegan P, Pazdur R: FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. *Clin Cancer Res* 2019, 25(13): 3753-3758.
- Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I: Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. *Cancers (Basel)* 2021, 13(19).
- Cheever MA, Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. *Clin Cancer Res* 2011, 17(11): 3520-3526.
- Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K: Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. *Urol Oncol* 2015, 33(5): 245-260.
- Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillesen SS, Sternberg CN, Berruti A, De Braud FGM et al: Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. *Cancer Treat Rev* 2020, 88: 102057.
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010, 363(5): 411-422.
- Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. *Urology* 2013, 81(6): 1297-1302.
- Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershsberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006, 24(19): 3089-3094.
- Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. *Cancer* 2009, 115(16): 3670-3679.
- Mulders PF, De Santis M, Powles T, Fizazi K: Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. *Cancer Immunol Immunother* 2015, 64(6): 655-663.
- Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG: Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. *J Natl Cancer Inst* 2017, 109(4).
- GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA et al: Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. *Clin Cancer Res* 2015, 21(16): 3619-3630.
- Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA et al: Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst* 2014, 106(11).
- Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearnsteyne E, Harmon M, Campogan D, Haynes H et al: Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. *Clin Cancer Res* 2018, 24(19): 4662-4671.
- Kibel AS, Inman BA, Pachynski RK, Vu T, Sheikh NA, Petrylak DP: Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. *J Natl Cancer Inst* 2022, 114(2): 310-313.
- Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L: Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. *Cancer Immunol Res* 2020, 8(12): 1496-1507.
- Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL: Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *J Natl Cancer Inst* 2020, 112(6): 562-573.
- Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP: Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. *Prostate Cancer Prostatic Dis* 2014, 17(3): 259-264.
- Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM et al: Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. *Prostate Cancer Prostatic Dis* 2020, 23(3): 517-526.
- Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH et al: Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. *Cancer Causes Control* 2018, 29(6): 581-588.

28. Steele KE, Tan TH, Korn R, Dacosta K, Brown C, Kuziora M, Zimmermann J, Laffin B, Widmaier M, Rognoni L et al: Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. *J Immunother Cancer* 2018, 6(1): 20.
29. Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC et al: Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. *Clin Cancer Res* 2017, 23(10): 2451-2459.
30. Jain HV, Sorribes IC, Handelsman SK, Barnaby J, Jackson TL: Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy. *Cancers (Basel)* 2021, 13(8).
31. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N et al: A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 2015, 21(17): 3862-3869.
32. Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D et al: Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. *Cancer Treat Res Commun* 2019, 19: 100116.
33. Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J et al: Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. *Clin Cancer Res* 2021, 27(6): 1623-1630.
34. Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C et al: Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. *J Immunother Cancer* 2021, 9(5).
35. Dorff T, Hirasawa Y, Acoba J, Pagano I, Tamura D, Pal S, Zhang M, Waitz R, Dhal A, Haynes W et al: Phase Ib study of patients with metastatic castrate resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. *J Immunother Cancer* 2021, 9(8).
36. Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD et al: IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). *J Immunother Cancer* 2021, 9(8).
37. Caram MEV, Ross R, Lin P, Mukherjee B: Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. *JAMA Netw Open* 2019, 2(4): e192589.
38. Pollard ME, Moskowitz AJ, Diefenbach MA, Hall SJ: Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. *Asian J Urol* 2017, 4(1): 37-43.
39. Tsaor I, Brandt MP, Juengel E, Manceau C, Ploussard G: Immunotherapy in prostate cancer: new horizon of hurdles and hopes. *World J Urol* 2021, 39(5): 1387-1403.
40. Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA: Emerging therapeutic targets for patients with advanced prostate cancer. *Cancer Treat Rev* 2019, 76: 1-9.
41. Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J et al: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. *Oncotarget* 2015, 6(20): 18192-18205.
42. Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R et al: Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. *Cancer Immunol Immunother* 2018, 67(1): 89-100.
43. Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukiela-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V et al: Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2022, 8(4): 546-552.
44. Comiskey MC, Dallos MC, Drake CG: Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. *Curr Oncol Rep* 2018, 20(9): 75.
45. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S et al: Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. *Clin Cancer Res* 2006, 12(11 Pt 1): 3394-3401.
46. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ: Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. *Cancer* 2008, 113(5): 975-984.
47. Sonpavde G, Slawin KM, Spencer DM, Levitt JM: Emerging vaccine therapy approaches for prostate cancer. *Rev Urol* 2010, 12(1): 25-34.
48. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL: ProstateVAC: a vector-based vaccine targeting PSA in prostate cancer. *Expert Opin Investig Drugs* 2009, 18(7): 1001-1011.
49. Sharp DW, Lattime EC: Recombinant Poxvirus and the Tumor Microenvironment: Oncolysis, Immune Regulation and Immunization. *Biomedicines* 2016, 4(3).
50. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J et al: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol* 2010, 28(7): 1099-1105.
51. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J et al: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol* 2019, 37(13): 1051-1061.
52. Chang J: Adenovirus Vectors: Excellent Tools for Vaccine Development. *Immune Netw* 2021, 21(1): e6.
53. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM: Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. *Int J Cancer* 2001, 94(6): 842-849.
54. Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C et al: Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). *J Immunother Cancer* 2021, 9(3).
55. Kimura T, Egawa S, Uemura H: Personalized peptide vaccines and their relation to other therapies in urological cancer. *Nat Rev Urol* 2017, 14(8): 501-510.
56. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U et al: Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. *Cancer Biol Ther* 2010, 10(12): 1266-1279.
57. Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K, Matsumoto H, Fukasawa S, Kohjimoto Y, Nakatsu H, Takenaka A et al: A randomized phase III trial of personalized peptide vaccination for



- castration-resistant prostate cancer progressing after docetaxel. *Oncol Rep* 2021, 45(1): 159-168.
58. Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G et al: A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. *Cancer Immunol Immunother* 2013, 62(6): 1041-1052.
  59. Filaci G, Fenoglio D, Nolè F, Zanardi E, Tomasello L, Aglietta M, Del Conte G, Carles J, Morales-Barrera R, Guglielmini P et al: Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. *Cancer Immunol Immunother* 2021, 70(12): 3679-3692.
  60. Zahm CD, Colluru VT, McNeel DG: DNA vaccines for prostate cancer. *Pharmacol Ther* 2017, 174: 27-42.
  61. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R et al: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. *J Clin Oncol* 2009, 27(25): 4047-4054.
  62. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P et al: DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. *Cancer Immunol Immunother* 2012, 61(11): 2161-2170.
  63. Teplensky MH, Dittmar JW, Qin L, Wang S, Evangelopoulos M, Zhang B, Mirkin CA: Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets. *Adv Healthc Mater* 2021, 10(22): e2101262.
  64. Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG: The clinical progress of mRNA vaccines and immunotherapies. *Nat Biotechnol* 2022, 40(6):840-854.
  65. Li M, Wang Z, Xie C, Xia X: Advances in mRNA vaccines. *Int Rev Cell Mol Biol* 2022, 372: 295-316.
  66. Karam M, Daoud G: mRNA vaccines: Past, present, future. *Asian J Pharm Sci* 2022, 17(4): 491-522.
  67. Zheng X, Xu H, Yi X, Zhang T, Wei Q, Li H, Ai J: Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. *Mol Cancer* 2021, 20(1): 160.